Drug Profile
CSL 689
Alternative Names: CSL-689; rVIIa-FPLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Blood coagulation factors; Recombinant fusion proteins
- Mechanism of Action Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemophilia A; Haemophilia B
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Haemophilia-A in Netherlands (IV, Infusion)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Haemophilia-A in Norway (IV, Infusion)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Haemophilia-B in Netherlands (IV, Infusion)